Prostate-specific antigen screening and 15-year prostate cancer mortality: A secondary analysis of the CAP randomised clinical trial

In this secondary analysis of a randomized clinical trial, a single invitation for PSA screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years. However, the absolute reduction in deaths was small.